Comparison of xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant mycobacterium tuberculosis

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 1846-1852

  Rufai, Syed Beenish ^a   Kumar, Parveen ^a   Singh, Amit ^a   Prajapati, Suneel ^a   Balooni, Veena ^a   Singh, Sarman ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; CLINICAL EFFECTIVENESS; CODON; CONTROLLED STUDY; CULTURE MEDIUM; DNA HYBRIDIZATION; DNA SEQUENCE; GENE SEQUENCE; HUMAN; INTERMETHOD COMPARISON; MOLECULAR PROBE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SPUTUM ANALYSIS; SPUTUM SMEAR; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EVALUATION STUDY; INDIA; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR DIAGNOSIS; PROCEDURES; PROSPECTIVE STUDY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; FALSE POSITIVE REACTIONS; HUMANS; INDIA; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84901684438     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03005-13     Document Type: Article

References (37)

1. Chiang CY, Van Weezenbeek C, Mori T, Enarson DA. 2013. Challenges to the global control of tuberculosis. Respirology 18:596-604. http://dx.doi.org/10. 1111/resp.12067.
2. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Hobsburg CR, Jr. 1991. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-532. (Pubitemid 23053828)
3. Somoskovi A, Parsons LM, Salfinger M. 2001. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respir. Res. 2:164-168. http://dx.doi.org/10.1186/rr54. (Pubitemid 34187923)
4. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. 2006. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low-and high-level resistance. J. Clin. Microbiol. 44:3659-3664. http://dx.doi.org/10. 1128/JCM.01054-06. (Pubitemid 46768798)
5. Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla. 2013. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point of care test. Lancet Infect. Dis. 13:349-361. http://dx.doi.org/10.1016/S1473-3099(13) 70008-2.
6. Li J, Xin J, Zhang L, Jiang L, Cao H, Li L. 2012. Rapid detection of rpoB mutations in rifampin resistant M. tuberculosis from sputum samples by denaturing gradient gel electrophoresis. Int. J. Med. Sci. 9:148-156. http://dx.doi.org/10.7150/ijms.3605.
7. Ahmad S, Mokaddas E, Fares E. 2002. Characterization of rpo B mutations in rifampin-resistant clinical Mycobacterium tuberculosis isolates from Kuwait and Dubai. Diagn. Microbiol. Infect. Dis. 44:245-252. http://dx.doi.org/10.1016/ S0732-8893(02)00457-1. (Pubitemid 36001980)
8. Mani C, Selvakumar N, Narayanan S, Narayanan PR. 2001. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J. Clin. Microbiol. 39:2987-2990. http://dx.doi.org/10.1128/JCM.39. 8.2987-2990.2001. (Pubitemid 32744028)
9. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralized use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495-1505. http://dx.doi.org/10.1016/S0140-6736(11)60438-8.
10. Makinen J, Marttila HJ, Marjamaki M, Viljanen MK, Soini H. 2006. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 44:350-352. http://dx.doi.org/10.1128/JCM.44.2.350-352.2006. (Pubitemid 43222221)
11. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. 2012. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J. Clin. Microbiol. 50:3712-3716. http://dx.doi.org/10.1128/JCM.01958-12.
12. Revised National Tuberculosis Control Programme. 2012. Guidelines on programmatic management of drug resistant TB (PMDT) in India. Ministry of Health & Family Welfare, New Delhi, India. http://tbcindia.nic.in/pdfs/ guidelines%20for%20pmdt%20in%20india%20-%20may% 202012.pdf.
13. Kumar P, Balooni V, Sharma BK, Kapil V, Sachdeva KS, Singh S. 2014. High degree of multidrug resistance and hetero-resistance in pulmonary TB patients from Punjab state of India. Tuberculosis 94:73-80. http://dx.doi.org/10.1016/j. tube.2013.10.001.
14. Kent PT, Kubica GP. 1985. Public health mycobacteriology: a guide for a level III laboratory. Centers for Disease Control and Prevention, Atlanta, GA.
15. Hain Lifescience GmbH. GenoTypeMTBDRplus, version 2.0 product insert. Nehren, Germany. http://www.hain-lifescience.de/en/instructions-for-use.html.
16. World Health Organization. 2008. Molecular line probe assay for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDRTB). World Health Organization, Geneva, Switzerland. http://www.who.int/tb/features- archive/policy-statement.pdf.
17. Boehme CC, Nabeta P, Hillemann D. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-1015. http://dx.doi.org/10.1056/NEJMoa0907847.
18. Becton, Dickinson & Company. BACTEC MGI-960 SIRE kit for the antimycobacterial susceptibility testing of Mycobacterium tuberculosis. http://www.bd.com/ds/technicalCenter/clsi/clsi-960sire.pdf. Becton, Dickinson & Company, Franklin Lakes, NJ.
19. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041. http://dx.doi.org/10.1128/AAC.01550- 10.
20. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, Gillis TP. 1998. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1853-1857. (Pubitemid 28311593)
21. Yang B, Koga H, Ohno H, Ogawa K, Fukuda M, Hirakata Y, Maesaki S, Tomono K, Tashiro T, Kohno S. 1998. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 42: 621-628. http://dx.doi.org/10.1093/ jac/42.5.621. (Pubitemid 28510620)
22. Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, Nachega JB, Warren RM, Schaaf HS. 2012. Rise in rifampicin monoresistant tuberculosis in Western Cape, South Africa. Int. J. Tuberc. Lung Dis. 16: 196-202. http://dx.doi.org/10.5588/ijtld. 11.0116.
23. Ridzon R, Whitney GC, McKenna MT, Taylor JP, Ashkar SH, Nitta AT, Harvey SM, Valway S, Woodley C, Cooksey R, Onorato IM. 1998. Risk factors for rifampin monoresistant tuberculosis. Am. J. Respir. Crit. Care Med. 157:1881-1884. http://dx.doi.org/10.1164/ajrccm.157.6.9712009.
24. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74:417-433. http://dx.doi.org/10.1128/MMBR.00016-10.
25. de Oliveira MM, da Silva Rocha A, Cardoso Oelemann M, Gomes HM, Fonseca L, Werneck-Barreto AM, Valim AM, Rossetti ML, Rossau R, Mijs W, Vanderborght B, Suffys P. 2003. Rapid detection of resistance against rifampicin in isolates of Mycobacterium tuberculosis from Brazilian patients using a reverse-phase hybridization assay. J. Microbiol. Methods 53:335-342. http://dx.doi.org/10. 1016/S0167-7012(02)00253-1. (Pubitemid 36412047)
26. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. 2005. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 43:3699-3703. http://dx.doi.org/10.1128/JCM.43.8.3699-3703.2005. (Pubitemid 41129648)
27. Singh A, Gopinath K, Singh N, Singh S. 15 November 2013. Deciphering the sequential events during the invivo acquisition of drug resistant in Mycobacterium tuberculosis. Int. J. Mycobacteriol. http://dx.doi.org/10.1016/j. ijmyco.2013.10.006.
28. Ma X, Wang H, Deng Y, Liu Z, Xu Y, Pan X, Musser JM, Graviss EA. 2006. rpoB gene mutations and molecular characterization of rifampinresistant Mycobacterium tuberculosis isolates from Shandong Province, China. J Clin Microbiol. 44:3409-3412. http://dx.doi.org/10.1128/JCM.00515-06. (Pubitemid 44413791)
29. Cavusoglu C, Hilmioglu S, Guneri S, Bilgic A. 2002. Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J. Clin. Microbiol. 40:4435-4438. http://dx.doi.org/10.1128/JCM.40.12.4435-4438.2002. (Pubitemid 35434927)
30. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM. 2006. Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J. Clin. Microbiol. 44:2485-2491. http://dx.doi.org/10.1128/JCM.00083-06. (Pubitemid 44092416)
31. Hilleman D, Rusch-Gerdes S, Boehme C, Ritchter E. 2011. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J. Clin. Microbiol. 49:1202-1205. http://dx.doi.org/10.1128/JCM.02268- 10.
32. Marlowe EM, Novak Weekley SM, Cumpio J, Sharp SE, Momeny MA, Babst A, Carlson JS, Kawamura M, PandoriM. 2011. Evaluation of the Cepheid Xpert MTB/RIF assay for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J. Clin. Microbiol. 49:1621-1623. http://dx.doi.org/10.1128/JCM. 02214-10.
33. Somoskovi A, Deggim V, Ciardo D, Bloemberg GV. 2013. Diagnostic implications of inconsistent results obtained with the Xpert MTB/RIF assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance. J. Clin. Microbiol. 51:3127-3129. http://dx.doi.org/10.1128/JCM.01377-13.
34. Foundation for Innovative New Diagnostics (FIND). 2011. Performance of Xpert MTB/RIF version G4 assay. FIND, Geneva, Switzerland. www.stoptb.org/wg/ gli/assets/documents/map/findg4cartridge.pdf.
35. Stevens W. 2012. Analysis of needed interface between molecular diagnostic tests and conventional mycobacteriology. 43rd Union World Conference on Lung Health, Kuala Lumpur, Malaysia.
36. Folkvardsen DB, Vibeke O, Thomsen Rigouts Leen Rasmussen EM, Bang D, Bernaerts G, Werngren J, Toro JC, Hoffner S, Hillemann D, Svensson E. 2013. Rifampicin hetereoresistance in Mycobacterium tuberculosis cultures detected by phenotypic and genotypic drug susceptibility test methods. J. Clin. Microbiol. 51:4220-4222. http://dx.doi.org/10.1128/JCM.01602-13.
37. Folkvardsen DB, Svensson E, Thomsen V, Rasmussen EM, Bang D, Werngren J, Hoffner S, Hillemann D, Rigoutsd L. 2013. Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J. Clin. Microbiol. 51:1596-1599. http://dx.doi.org/10.1128/JCM.00472-13.